Detection Kit for K-RAS Gene Mutations Developed for Lung Cancer Patients

K-RAS mutation status is a strong predictor of resistance to therapy with tyrosine kinase inhibitors.

DxS Ltd. (Manchester, UK), a company specializing in molecular diagnostics, recently announced the launch of their K-RAS Mutation Detection kit. This kit uses a real-time polymerase chain reaction (PCR) format to detect seven key mutations in the K-RAS gene. DxS says that the kit can detect <1% of mutant DNA in a background of wild type genomic DNA and has a limit of detection of 10 copies or below.

Dr. Stephen Little, CEO of DxS Ltd) said, "K-RAS mutation status is emerging as an important predictor of drug response. At DxS we are committed to providing the tools that doctors will need to ensure that their patients are given the best choice of therapy. This kit is the latest addition to our portfolio of products for personalized medicine.”


Related Links:
DxS Ltd.